Sepsis Clinical Trial
— CLEAR SepsisOfficial title:
Noninvasive Hemodynamic Monitoring Utilizing ClearSight TM System in Suspected Sepsis Patients Presenting to the Emergency Department (CLEAR SEPSIS)
NCT number | NCT03231956 |
Other study ID # | 2017-04 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 29, 2017 |
Est. completion date | June 30, 2022 |
To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).
Status | Recruiting |
Enrollment | 182 |
Est. completion date | June 30, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Venous Blood Lactate Groups Inclusion Criteria: - = 18 years of age at the time of enrollment - Any combination of acute symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection - ED Physician confirms likely hospital admission (> 50%) due to suspicion of infection - ED Physician confirms intention to order both blood cultures and venous blood lactate levels - Ability to enroll patient and begin ClearSight™ monitoring within three (3) hours of ED presentation Exclusion Criteria: - Initial venous blood lactate measured > 3 hours after ED arrival - Pre-existing infection for which patient is being treated with antibiotics as an outpatient - Prisoners - Pregnant women - Any previous medical condition with life expectancy of < 3 months (patients with ESRD and heart failure are not excluded) - DNR or comfort care order preexisting to ED visit or established in the ED - Palliative care or hospice consult in the ED - Known severe aortic insufficiency - Known history of Raynaud's disease - Poor follow-up candidate in the opinion of the Investigator - Current or planned enrollment in an investigational trial that in the opinion of the Investigator may significantly affect hemodynamic data collection. Control Sepsis Mimic Inclusion Criteria: - =18 years of age at the time of enrollment - Presents to the ED with a chief complaint consistent with a minor infection (upper respiratory infection, soft tissue infection, viral infection) or an asthma or COPD exacerbation on whom the treating physician is not ordering labs for blood cultures or lactate levels - Ability to enroll patient and begin ClearSight™ monitoring within three (3) hours of ED presentation. Exclusion Criteria: - Pre-existing infection for which patient is being treated with antibiotics as an outpatient - Prisoners - Pregnant women - Any previous medical condition with life expectancy of < 3 months (patients with ESRD and heart failure are not excluded) - DNR or comfort care order preexisting to ED visit or established in the ED - Palliative care or hospice consult in the ED - Known severe aortic insufficiency - Known history of Raynaud's disease - Poor follow-up candidate in the opinion of the Investigator - Current or planned enrollment in an investigational trial that in the opinion of the Investigator may significantly affect hemodynamic data collection. - Treating physician is planning on ordering either a lactate or blood cultures on the patient. |
Country | Name | City | State |
---|---|---|---|
United States | Ascension St. John Hospital | Detroit | Michigan |
United States | Detroit Receiving Hospital | Detroit | Michigan |
United States | Sinai-Grace Hospital | Detroit | Michigan |
United States | Beaumont Hospital, Royal Oak | Royal Oak | Michigan |
United States | Beaumont Hospital, Troy | Troy | Michigan |
Lead Sponsor | Collaborator |
---|---|
Edwards Lifesciences |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite outcome | Increase in modified Sequential Organ Failure Assessment (mSOFA) score = 1 resulting in ICU admission / death. | Within 72 hours of presentation | |
Primary | Venous Blood Lactate clearance | Venous Blood Lactate clearance | Within 24 and 72 hours of presentation | |
Primary | Length of Stay | Emergency Department length of stay, ICU length of stay, and Hospital length of stay | 30 days | |
Primary | Recidivism | Recidivism within 30 days of the index hospital visit | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |